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The KCL031 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro and in vivo assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Resource table
Name of stem cell
line
KCL031
Institution King's College London, London UK
Derivation team
Neli Kadeva, Victoria Wood, Glenda Cornwell, Stefano
Codognotto, Emma Stephenson
Contact person
and email
Dusko Ilic, email: dusko.ilic@kcl.ac.uk
Date
archived/stock
date
Aug 02, 2011
Type of resource Biological reagent: cell line
Sub-type Human pluripotent stem cell line
Origin Human embryo
Key marker
expression
Pluripotent stem cell markers: NANOG, OCT4, TRA-1-60,
TRA-1-81, alkaline phosphatase (AP) activity
Authentication Identity and purity of line conﬁrmed
Link to related
literature
(direct URL
links and full
references)
1) Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J.,
Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D.,
2013. Strategy for the creation of clinical grade hESC line
banks that HLA-match a target population. EMBO Mol.
Med. 5 (1), 10–17. doi: 10.1002/emmm.201201973
http://www.ncbi.nlm.nih.gov/pubmed/23161805
2) Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P.,
Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J.,
Moore, H.D., Murray, H., Kunath, T., 2015. The molecular
karyotype of 25 clinical-grade human embryonic stem cells
lines. Sci. Rep. 5, 17258. doi: 10.1038/srep17258
http://www.ncbi.nlm.nih.gov/pubmed/26607962
3) Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D.,
Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M.,
Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and
feeder-free propagation of human embryonic stem cells
under xeno-free conditions. Cytotherapy. 14 (1), 122–128.
doi: 10.3109/14653249.2011.623692
http://www.ncbi.nlm.nih.gov/pubmed/22029654
4) Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N.,
Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D.,
2012. Derivation and propagation of human embryonic
stem cell lines from frozen embryos in an animal
product-free environment. Nat. Protoc. 7 (7), 1366–1381.
doi: 10.1038/nprot.2012.080
http://www.ncbi.nlm.nih.gov/pubmed/22722371
Information in
public
databases
KCL031 is a National Institutes of Health (NIH) registered hESC
line
NIH Registration Number: NIHhESC-14-0263
http://grants.nih.gov/stem_cells/registry/current.htm?id=672
Ethics
The hESC line KCL031 is derived under license from the UK
Human Fertilisation and Embryology Authority (research li-
cence numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics Com-
mittee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the ex-
periments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.
Stem Cell Research 16 (2016) 195–198
⁎ Corresponding author.
E-mail address: dusko.ilic@kcl.ac.uk (D. Ilic).
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2. Resource details
Consent signed Nov 26, 2008
Embryo thawed Jun 29, 2011
UK Stem Cell Bank Deposit
Approval
Reference: SCSC12-37
Sex Male 46, XY
Grade Clinical
Disease status Healthy/Unaffected
Karyotype (aCGH)
50 kb deletion at 7q22.3
(105,465,968–105,516,305).
SNP Array
Loss at 8q24.23 (136,718,037–136,837,768)
(Canham et al., 2015)
DNA ﬁngerprint
Allele sizes (in bp) of 16 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21
(Jacquet et al., 2013)
HLA typing
HLA-A 02, 24; B 51, 52; Bw 4; C 12, 14; DRB1 11,
15; DRB3 02; DRB5 01; DQB1 03, 06 (Jacquet
et al., 2013; Canham et al., 2015)
Viability testing Pass
Mycoplasma Negative
Sterility Pass
Pluripotent markers
(immunostaining)
(Fig. 1)
NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layer differentiation
in vitro (immunostaining)
(Fig. 2)
Endoderm: AFP (α-fetoprotein)
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth
muscle)
Three germ layer differentiation
in vivo (teratomas)
(Fig. 3)
Endoderm: AFP, GATA4
Ectoderm: TUBB3, GFAP (glial ﬁbrillary acidic
protein)
Mesoderm: DES (desmin), Alcian Blue and pe-
riodic acid–Schiff (PAS)-stained cartilage
Targeted differentiation (Fig. 4)
Cardiomyocytes: TNNT2 (cardiac troponin
T) immunostaining
Sibling lines available No
We generated KCL031 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2) and in vivo
(Fig. 3), aswell as targeted differentiation into cardiacmyocytes (Fig. 4).
Molecular karyotyping using array comparative genomic hybridiza-
tion aCGH identiﬁed deletion at 7q22.3 (105,465,968–105,516,305).
Whole-genome single nucleotide polymorphism (SNP) array analysis
detected loss at 8q24.23 (136,718,037–136,837,768) (Canham et al.,
2015). The gain contains no genes and it has been also reported previ-
ously to occur in healthy individuals from worldwide population
(Macdonald et al., 2014). Estimated frequency in the human population
is 3.85% (Canham et al., 2015).
Donors were tested negative for Human Immunodeﬁciency Virus 1
(HIV1), Hepatitis B (HepB, HCB) and C Virus (HepC, HCV). We did not
retest the line.
We also generated research grade of KCL031 line that is adapted to
feeder-free conditions.
3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.5) were created on Aug. 10, 2007.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 — R.1 (http://www.hfea.gov.uk/2999.html). The donor
Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
ﬁbers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 μm.
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couple signed the consent on Nov. 26, 2008. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 7— R.4. HFEA Code
of Practice Edition 7— R.1 was in effect until Dec. 09, 2007, whereas 7—
R.4 was in effect: Oct. 02, 2008–Sep. 30, 2009.
3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC colo-
nies were expanded and cryopreserved at the third passage.
3.4. Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
3.5. Pluripotency
Pluripotency in vitro was assessed using two different techniques:
enzymatic activity assay [alkaline phosphatase (AP) assay] and immu-
nostaining as described (Ilic et al., 2012; Stephenson et al., 2012).
3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Stephenson et al., 2012; Petrova
et al., 2014). Targeted differentiation in cardiomyocytes followed the
protocols described earlier (Laﬂamme et al., 2007; Jacquet et al., 2015).
Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 50 μm.
Fig. 3. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not invade surrounding tissue. Sections are counterstained with hematoxylin and eosin and
speciﬁc stains are brown (immunohistochemistry) or light blue (Alcian blue). Germ layer markers: Alcian blue–PAS-stained cartilage and DES for mesoderm, TUBB3 and GFAP for
ectoderm, GATA4 and AFP for endoderm. Positive immunostaining for complex IV type II marker conﬁrms the human origin of the tumor (adjacent section of the one stained for
desmin). Scale bars are 100 μm.
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3.7. Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA ex-
traction robot according to the manufacturer's instructions. Ampliﬁca-
tion of polymorphic microsatellite markers was carried out as
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
3.9. Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in details (Canham et al.,
2015).
3.10. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al.,
2013). HLA typing was also performed independently by other group
(Canham et al., 2015).
4. Author disclosure statement
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